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Ploidy-Seq: inferring mutational chronology by
sequencing polyploid tumor subpopulations
Ankit Malhotra1†, Yong Wang2†, Jill Waters2, Ken Chen3, Funda Meric-Bernstam4,5, Ira M Hall6,7*
and Nicholas E Navin2,3,8*

Abstract
Human cancers are frequently polyploid, containing multiple aneuploid subpopulations that differ in total DNA
content. In this study we exploit this property to reconstruct evolutionary histories, by assuming that mutational
complexity increases with time. We developed an experimental method called Ploidy-Seq that uses flow-sorting to
isolate and enrich subpopulations with different ploidy prior to next-generation genome sequencing. We applied
Ploidy-Seq to a patient with a triple-negative (ER-/PR-/HER2-) ductal carcinoma and performed whole-genome
sequencing to trace the evolution of point mutations, indels, copy number aberrations, and structural variants in
three clonal subpopulations during tumor growth. Our data show that few mutations (8% to 22%) were shared
between all three subpopulations, and that the most aggressive clones comprised a minority of the tumor mass.
We expect that Ploidy-Seq will have broad applications for delineating clonal diversity and investigating genome
evolution in many human cancers.

Background
Genome evolution is challenging to study in human patients, because we cannot ethically sample the patient at
multiple time points during the progression of the disease.
Even when samples can be obtained at different time points
[1-3], the tumor genome has usually been remodeled by
chemotherapy, making it difficult to observe its natural
course of evolution. An alternative approach is to reconstruct genome evolution ex post facto from a single tumor
sample. As tumor cells evolve, they form distinct lineages
and subpopulations as they mutate and encounter selective
pressures, resulting in intratumor heterogeneity. While
clonal diversity is considered ‘bad news’ from a clinical
standpoint, it provides a permanent record of the mutations
that occur during tumor evolution. By assuming that mutational complexity increases over time, we can use mutations
as stable markers of evolution to reconstruct the relative
chronology of the mutations during the natural history of
the disease.
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In our previous work, we reconstructed the evolution of
breast cancer genomes using copy number alterations
(CNAs) as stable markers of evolution [4,5]. Several other
approaches have also been developed to resolve intratumor
genomic heterogeneity. In several studies, next-generation
sequencing was performed on bulk tumors to measure mutation frequencies, which were normalized by copy number
to estimate tumor subpopulation fractions [3,6,7]. While
this approach can resolve some population substructure, it
is inherently unable to distinguish which combinations of
mutations co-exist in any particular subpopulation. Another approach involves spatially sampling distinct regions
within a tumor for exome sequencing to reconstruct the
evolutionary lineage of the tumor cells [8-10]. While this
approach can resolve spatially segregated subpopulations, it
cannot resolve multiple subpopulations that are intermixed
in single regions within the tumor. An alternative approach
is to use single cell sequencing methods [11-14], which
have the capability of fully resolving admixtures of genetically distinct clones. While powerful, these methods are currently limited by the number of cells that can be analyzed
due to considerable associated costs. Due to these technical
and economical limitations, the clonal diversity and patterns of genome evolution still remain poorly understood
in most human cancers.

© 2015 Malhotra et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
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Triple-negative (ER-/PR-/Her2-) breast cancers (TNBCs)
are particularly amenable for lineage tracing studies, since
they display extensive intratumor genomic heterogeneity
[7] and show very high numbers of genomic mutations
[7,11,15]. These mutations can serve as stable markers of
evolution for reconstructing the natural history of the
tumor. TNBCs are also of considerable interest to the clinical community, because they have the poorest 5-year survival rates and cannot be treated with many targeted or
hormonal therapies [16,17]. Thus, there is a strong interest
in improving our fundamental understanding of how these
tumors evolve genomic mutations and generate intratumor
heterogeneity that confounds clinical diagnostics and treatment of patients.

Methods
Tumor sample

The de-identified frozen breast tumor sample was obtained
from the Cooperative Human Tissue Network (CHTN).
Genomic data from this tumor sample were reported in two
previous studies [4,11]. Histopathological analysis classified
the tumor as an invasive ductal carcinoma, Richardsonbloom grade (III) with significant immune cell infiltration
and poor differentiation. The tumor sample stained negative
for estrogen receptor, progesterone receptor and Her2 receptor by immunohistochemistry, and was therefore classified as triple-negative (ER-/PR-/Her2-).
Human subjects

No human subjects participated in this study. The ductal
carcinoma sample was obtained as a de-identified frozen
tumor specimen from the Cooperative Human Tissue
Network (CHTN). This study was approved by the Cold
Spring Harbor IRB regulatory committee on 15 June 2010
under exemption 45 CFR.46.101(b)(4).
Data access

The data from this study have been uploaded to the Sequence Read Archive (NCBI) and are available for download under accession SRP013572.
Ploidy-Seq

Nuclei were isolated from cell lines and from the frozen
tumor using an NST-DAPI buffer and 0.1% DNase-free
RNase A. The frozen tumor sample was macrodissected
and nuclei were isolated from two regions (R1 and R2)
for FACS by finely mincing a tissue in a Petri dish in 1.0
to 2.0 mL of NST-DAPI buffer. The nuclear suspensions
were filtered through 37-μm plastic mesh prior to flowsorting. Prior to FACS we performed cytometric analysis
of ploidy distributions using the LSRII system (BD Biosciences). A small amount of prepared nuclei from each
tumor sample was mixed with a diploid control sample
(derived from a lymphoblastoid cell line of an apparently

Page 2 of 16

normal person) to accurately determine the diploid peak
position within the tumor DNA content distribution.
Nuclei were subsequently flow-sorted on the AriaII (BD
Biosciences) by gating cellular distributions with differences in their total genomic DNA content according to
DAPI intensity. Nuclei from each ploidy distribution
(1.7 N, 2 N, 3.1 N, and 3.3 N) were collected in separate
1.5 mL tubes and DNA was isolated and purified using
the Qiagen QiaAMP mini kit (cat #51304).
Next-generation sequencing

We acoustically sonicated 1ug of purified DNA to 200 to
300 bp using the Covaris Sonicator S220. Libraries were
constructed using NEBNext DNA library Prep Master
Mix Set for Illumina (New England Laboratory, #F6040L)
for end-repair, 3′adenylation and ligation according to
manufacturer’s instructions. The MinElute PCR Purification Kit (Qiagen, #28006) was used for the purification
steps during library prep. After agarose electrophoresis the
250 to 350 bp fraction was excised for purification. We
then performed eight cycles of PCR following manufacturer’s direction, using PE5/7 primers (Illumina Inc).
Agencourt AMPure XP (Beckman Coulter, #A63881) was
used for final purification. Final concentration was measured by quantitative PCR using the KAPA Library Quantification Kit (KAPA Biosystems, KK4835) and ABI
PRISM real-time machine (Applied Biosystem 7900HT)
and the size distribution was determined using the 2100
Bioanalyzer (Agilent). Each library was run at 100 singleend cycles on the Illumina HiSeq2000 or GA2 systems
using four to eight flow cell lanes. Data was processed
using the CASAVA 1.8.1 pipeline (Illumina Inc.) and sequence reads were converted to FASTQ files.
Data processing and alignment

Sequence reads in FASTQ format were mapped to the
human assembly US National Center for Biotechnology
Information (NCBI) build 36 (hg18) using the BurrowsWheeler alignment tool (BWA version 0.6.0) [18] with default parameters and sample option to create SAM files
with correct mate pair information, with a read group tag
that includes the sample name. We then used Samtools
(0.1.16) [19] to convert SAM files to compressed BAM
files and sort the BAM files by chromosome coordinate.
The Genome Analysis Toolkit (GATK v1.4-37) was used
to locally realign the BAM files at intervals that may have
insertion/deletion (indel) alignment errors before PCR duplicate marking with Picard (version 1.56) [20].
Single nucleotide and indel variant detection

We used GATK UnifiedGenotyper to detect single nucleotide variants (SNVs) and small indels [21]. We then used the
GATK variant recalibrator to filter the output at default sensitivity level. Recalibration training sets included hapmap
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3.3, dbSNP build 132, Omni 2.5 M chip, and Mills. Annotations used for training included variant quality score by
depth (QD), mapping quality rank sum score, read position rank sum score, mapping quality (MQ), coverage
depth (DP), and strand bias (FS). We required a minimum
base quality (mbq) of 20 for the base to be considered during variant detection. Coverage depth at a given locus of
greater than 2,500 reads was down sampled. All tumor
subpopulation samples (H, AA, and AB) were processed
together with the Diploid (D) sample to generate a single
VCF4 file. Somatic variants were distinguished from germline variants by excluding mutations sites present in the
Diploid sample. We then used GATK SelectVariants to
separate SNVs and indels into two VCF4 files for downstream annotation. During variant calling we required a
minimum coverage depth of 20 and minimum number of
variants reads of 5 to call SNVs or indels.
Copy number detection

Copy number alterations were detected from read depth
data using the variable binning method [12]. Briefly, copy
number is calculated from read density, by dividing the
genome into ‘bins’ and counting the number of unique
reads in each bin. To determine interval sizes we simulated
sequence reads by sampling 200 million sequences of
length 48 from the human reference genome (HG18/
NCBI36) and introduced single nucleotide errors with a frequency typically encountered during Illumina sequencing.
These sequences were mapped back to the human reference genome using BWA and filtered for unique mappings.
We assigned a number of bins to each chromosome based
on the proportion of simulated reads mapped. We then divided each chromosome into bins with an equal number of
simulated reads. This resulted in 50,009 genomic bins with
no bins crossing chromosome boundaries. The median
genomic length spanned by each bin is 54 kb. This variable
binning efficiently reduces false deletion events when
compared to uniform length-fixed bins. We then applied
Loess normalization to correct for GC bias. The copy number profiles were then segmented using the KolmogorovSmirnov (KS) statistical test [22].
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generate larger contigs from overlapping reads (−f < mean
insert size > −s < insert size standard deviation > −r 100).
All merged and unmerged reads were aligned to the reference genome using BWA-SW [24] using sensitive settings
(−z 10 -H). Split-read mappings with at least 25-bp of
non-overlap with an adjacent mapping on the query sequence were extracted from the BAM file, converted to
BEDPE format [25] and subjected to strict duplicate removal using dedupDiscordantsMultiPass (−s 3).
Split-read mappings were clustered into breakpoint
calls using a custom algorithm (SRM). SRM first
converts split-read mappings into predicted breakpoint
intervals (+/− 1-bp) and clusters intervals where both
ends overlap one another and predict the same variant
type (for example, deletion). SRM then performs an ‘all
by all’ comparison of all split-read mappings within each
cluster to identify the breakpoint that has the most
supporting split-reads. This breakpoint is reported as
representative of the cluster. In order to maximize the
sensitivity of presence/absence genotyping, reads from
all samples (for example, AA, AB, H, and D) were combined before clustering, and after clustering the number
of reads from each sample were counted to determine
patterns of SV sharing among the samples.
To reduce false positives arising due to read mapping and
library construction artifacts, breakpoint calls were filtered
using the following criteria: (1) the breakpoint was defined
by at least three reads; (2) the breakpoint call was at least
50-bp in size; (3) neither of the two breakpoints overlapped
a simple sequence or satellite repeat by more than 50%, as
determined by running bedtools pairToBed (−type either -f
0.5) against a union of the UCSC ‘simpleRepeat’ track and
both simple and satellite repeat annotations from the
‘RepeatMasker’ track; (4) the mean mapping quality of the
clustered mappings was greater than 30; and (5) the splitread mappings identifying a breakpoint were staggered by a
total of at least 3-bp on the non-breakpoint end. This last
step was done to remove false positives from multiple exact
matching reads from different samples (which can occur
due to alignment artifacts).
Detection of structural variants with CREST

Detection of structural variants by split read mapping (SRM)

Paired-end reads (readpairs) were aligned to the reference
genome (hg18) using NOVOALIGN with an index word size
of 14 and step size of 1 (−k 14 -s 1) using ‘Random’ mode
with empirically estimated insert size and standard deviation. We extracted all readpairs where one or more read
did not align to the reference genome, or where one or
more read had been soft-clipped by at least 25 bp. Since the
reads could be unmapped or soft-clipped due to poor quality, we removed all readpairs that had more than 4% N bases
in either of the reads. The remaining readpairs were written
to fastq files and fed into the FLASH program [23] to

We ran the CREST pipeline [26] using default settings on
each of the subpopulation (AA, AB, H, and D) bam files,
which were generated by alignment with BWA. The pipeline
involves four steps. First, putative breakpoints indicated by
at least two soft-clipped reads were extracted from each
chromosome. Second, putative somatic breakpoints in each
of the three cancer genomes were generated by subtracting
those that were also detected in the matched normal genome. Third, breakpoint sequences were assembled by CAP3
[27] using soft-clipped reads, and were aligned to the reference genome using BLAT to identify split-read mappings. A
breakpoint was called if a pair of identical breakpoint
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positions were identified from the BLAT alignment of two
distinct assembled breakpoint sequences. Calls obtained by
CREST and SRM were combined by comparing their coordinates and variant types. Variants of the same type where
both ends overlapped one another (+/− 10 bp) were considered to be due to the same underlying somatic mutation,
and the call from SRM was retained.
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strategy as in the D line, except that we required at least
two aligned reads to produce a positive genotype.
Finally, calls obtained by CREST and SRM were combined by comparing their coordinates and variant types.
Variants of the same type where both ends overlapped
one another (+/− 10 bp) were considered to be due to the
same underlying somatic mutation, and the call from
SRM was retained.

SV breakpoint assembly, validation, and genotyping

To validate breakpoints from SRM and CREST we performed de novo breakpoint assembly precisely as in our
previous study [28,29] using a modified version of the
SGA assembler. Briefly, we modified the sga walk function to report all walks from all connected components
of the string graph. This modification allows for efficient
assembly of low frequency somatic variants. For each
breakpoint predicted by SRM or CREST, we extracted
readpairs that mapped within 500-bp of the predicted
breakpoints, including readpairs with one unmapped
read. We then ran the following assembly pipeline: sga
preprocess (default), sga index (−−no-reverse), sga correct
(−k 13 -x 2 -d 128), sga index on the error corrected
reads (default), sga rmdup (default), sga overlap (−m 15),
sga assemble (−m 15 -d 0 -g 0 -b 0 -l 100), and our
modified version of sga walk (−d 10000 –componentwalks). Resulting contigs were aligned to the reference
genome using BWA-SW (v.0.5.9) [24]. Split-mappings
with at least 25 bp of non-overlap with an adjacent mapping on the query sequence were extracted from the
BAM file and converted to BEDPE format, where each
predicted breakpoint was represented by a 3-bp interval.
We then used pairToPair (−type both) from the BEDTools software suite [25] to assess whether the original
breakpoint calls were validated by split-mapping contigs.
We considered a call to be validated if the breakpoints
predicted by de novo assembly overlapped with the original breakpoints predicted by SRM/CREST and were of
the same variant class (for example, deletion). We next
performed a more sensitive breakpoint genotyping step
in order to exclude germline SV breakpoints that may
have been misclassified as somatic mutations due to inadequate coverage in the diploid (D) sample, and to obtain more accurate patterns of mutation sharing among
the tumor subpopulations. We aligned all of the raw
reads from each of the four samples to the library of
breakpoint-containing contigs using BWA (default options). We considered a breakpoint to be present in the
D sample (and thus to be a germline SV) if one or more
reads from the D sample aligned to the breakpointcontaining contig with at least 20 aligned bases on either
side of the novel junction. For the resulting somatic
breakpoints that were not detected in D, we determined
their presence/absence among the three tumor subpopulations using the same breakpoint contig alignment

Detection of loss of heterozygosity (LOH)

To map LOH events we first defined a set of 1,386,955
high confidence heterozygous germline SNPs from the
GATK callset using the following criteria: (1) the SNP was
determined by GATK to have a heterozygous genotype in
the normal diploid (D) sample; and (2) the alternate SNP
allele was present at a frequency of 0.25 to 0.75 in the D
sample, as determined by counting the number of aligned
reads that contained the alternate versus the reference
SNP allele. At each of these SNPs and for each of the three
tumor samples (AA, AB, and H) we then calculated the
minor allele frequency (MAF), which is defined as the
minimum of the alternate and reference allele frequencies.
We measured the mean MAF in 1-mb sliding windows
(not counting assembly gaps), where adjacent windows
overlapped by 500 kb, and defined LOH blocks as genomic intervals in which the mean MAF in a given sample
was less than 0.25.
Databases annotation

Single nucleotide variants and indels were annotated using
Annovar [30] (version 2011 Nov20) to classify variants as
synonymous, non-synonymous, missense, or frameshift
point mutations and frameshift indels. Mutations were then
annotated using the COSMIC database [31] and the cancer
gene census database by intersecting regions using BEDtools
(v2.14.2) [25]. A Perl script was developed to run all of the
annotation steps automatically and pool annotation results
into one final file.
Comparative analyses

Set theory operations (that is, union, intersect) were performed using custom perl scripts to parse the VCF4 files
generated by the GATK Unified Genotyper. To build
Venn Diagrams, the following filtering criteria were used:
for somatic SNVs we required a minimum of 20X coverage depth with ≥5 variant reads from all tumor and normal samples, for indels we used coverage depth cutoff of
20 and variant reads of five for tumor samples. For copy
number alterations we used mean KS segments with
ratio ≥1.4 and ≤0.8, and for structural variants we used
sites that were validated by de novo assembly and confirmed
to be absent from the D lines by alignment-based genotyping (see SV section above). Venn diagram plots were constructed using a R package named Vennerable [32].
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Circos plots

Circular genomic visualization plots were constructed using
Circos [33] (V 0.55) using BED files generated from variant
calling and Annovar annotation. SNVs, indels, LOHs, SVs
altering copy number were plotted as highlights. CNA were
plotted as histograms. Balanced SVs were plotted as ribbons.
Calculation of neighbor-joining trees

Neighbor-joining trees [34] were constructed using Matlab
(Mathworks) by calculating distance matrices using either
Euclidean distance (for copy number data) or hamming
distances (for point mutations, indels, and structural variants). For Hamming distance matrices we calculated binary vectors of mutations by denoting the presence (1) or
absence (0) of variants in the VCF4 files generated by
GATK. All neighbor-joining trees were finally re-rooted by
the diploid node in Matlab (Mathworks).
TCGA data comparisons

Genes with non-synonymous point mutations that showed
significant POLYPHEN (>0.5) or SIFT scores (>0.1) were
compared to the ‘Breast Invasive Carcinoma, TCGA 2012’
and ‘TCGA provisional’ databases to determine the frequencies in patient cohorts. The cBio portal for Cancer
Genomics (Memorial-Sloan Kettering) tool was used to
compare the mutation sets to these databases [35].
Pathway and network analysis

Pathways analysis was performed using the KEGG database
(Kyoto) and DAVID (v6.7, NIH) analysis tool. GenBank
identifiers associated with nonsynonymous mutations in
genes that had significant POLYPHEN (>0.5) or SIFT scores
(>0.1) were used for analysis. Pathways with significant enrichment scores (P >0.01) over the background frequency,
normalized by the total number genes, were reported. Network analysis was performed using Ingenuity Pathway Analysis (Qiagen, Inc.). Multiple networks were identified using
the non-synonymous point mutation data from all of the
subpopulations, by calculating scores and identifying the
networks with the highest scores. Briefly, the network score
is based on the hypergeometric distribution and is calculated with the right-tailed Fisher’s exact test. The score
takes into account the number of network molecules in the
network and its size, as well as the total number of network
eligible molecules analyzed and the total number of molecules in the Ingenuity Knowledge Base that could potentially be included in networks. The network data was
plotted using Cytoscape [36].
Computational inference of tumor subpopulations

SciClone [37] and PurBayes [38] were applied to mixed
BAM files at varying coverage depths (30X, 50X, 100X)
to estimate clonal subpopulations using the mutation
frequency data and copy number profiles. SciClone is an
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R package that was downloaded as a compressed file from
GitHub [39]. The run.R script was executed using the
VCF4 somatic mutation variant file and the segmented
copy number states to perform clustering and density estimations. The plot.R function was used to plot the allele
frequency distributions and density estimations. Default
parameters were used for running the scripts, except for
the minimum depth parameter which was set to 50, 20
and 15 for the 100X, 50X, and 30X mixed BAM files. For
the subpopulations, T10AA, T10AB, and T10H, the minimum depth was set to 20. We used PurBayes v1.3 to estimate the number of sub-clonal populations from the
mixed population data. Using SNVs estimated from mixed
data with coverage of 100x, 50x, and 30x respectively, we
filtered SNPs in dbSNP, and selected only SNVs that were
present in copy neutral regions (Logratio between −0.5
and 0.5, or −1 and 1, or −2 and 2). We further reduced the
list of SNVs to only the SNVs present in the exonic
regions (Exons defined by Gencode Manual Ver. 3 downloaded from the UCSC Genome Browser) and having
minimum read coverage of 30 (ref + alternate). These
SNVs were then analyzed with the PurBayes R package
using default parameters (M = NULL, Z = NULL, pop.
max = 5, prior = NULL, burn.in = 50000, n.post = 10000,
fn.jags = ‘PB.jags’, plot = TRUE).

Results
We developed a novel approach called Ploidy-Seq to study
genomic diversity and mutational evolution in human cancers. The principle of this method is to use flow-sorting to
purify and enrich subpopulations from polyploid tumors
prior to next-generation sequencing analysis. Our cytometric data (Additional file 1: Figure S1) and previous studies
[4] suggest that approximately half of all breast tumors show
multiple distributions of ploidy, as do many other solid cancers types [40]. These data suggest that Ploidy-Seq will have
broad applications for studying genome evolution in many
human cancers. After enrichment and isolation, we perform
whole-genome deep-sequencing of the tumor subpopulations to detect the full spectrum of somatic mutations, including point mutations, indels, CNAs, structural variants,
and loss of heterozygosity (LOH). From these data we apply
set theory operations and lineage analysis to infer the relative chronology of mutations that occurred during tumor
evolution.
We applied Ploidy-Seq to study an invasive ductal carcinoma from a 53-year-old triple-negative (ER-/PR-/Her2-)
breast cancer patient. Histopathology revealed a high-grade
(III) invasive ductal carcinoma with significant immunocyte
infiltration. We flow-sorted nuclei from two regions (R1 and
R2) in the frozen tumor sample (Figure 1a). The upper region showed a diploid distribution (2 N) and a hypodiploid
(H) distribution (1.7 N). The lower regions showed a diploid
distribution (2 N) and two aneuploid distributions at 3.1 N
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Figure 1 Ploidy-Seq approach. Outline of the approach for isolating and enriching tumor subpopulation by differences in total DNA content
prior to next-generation sequencing. Images and cytometric data are displayed from the triple-negative breast tumor case. (a) Two regions (R1
and R2) were sampled and nuclear suspensions were prepared and stained with DAPI. (b) The nuclei were flow-sorted and different distributions
of ploidy were gated. (c) Cells from each ploidy peak were isolated into separate tubes and the DNA was isolated and used to prepare libraries
for next-generation sequencing. (d) Somatic mutations from each subpopulation were detected and set theory operations were performed to
identify early intermediate or late mutations. (e) The composition of the tumor subpopulations relative to the total mass were calculated from
the number of events in the cytometric data.

(AA) and 3.3 N (AB). From the cell count cytometric data
we estimated the total proportions of cells in the bulk tumor
(Figure 1b). We collected millions of nuclei from each region and ploidy peak and performed whole-genome deepsequencing on the four subpopulations (D, H, AA, and AB)
at 53X mean coverage on the Illumina HiSeq2000 platform
using 100 bp paired-end reads (see Methods).
The sequence reads were aligned to the human genome
using BWA and variants were detected using a comprehensive data processing pipeline (Methods and Additional file 1:
Figure S2). Point mutations and indels were detected using
GATK [21], copy number profiles were detected using varbins [12], and structural variants (SVs) were detected using
CREST [26] and a custom split-read mapping pipeline
(methods). Somatic mutations were distinguished from
germline variants based upon their presence in one or more

tumor subpopulations (H, AA, and AB) but not the diploid
subpopulation (D), which derive from normal infiltrating
cells. After removing germline variants and applying various filters (methods), we detected a total of 17,630 single
nucleotide variants (SNVs), 4,510 indels, 657 structural variants (SVs), and 312 copy number alterations (CNAs). In
the coding regions we detected 83 non-synonymous SNVs,
four frameshift indels, and two SVs (Additional file 2:
Tables S1-S3).
Identifying unique and common somatic mutations

We applied set theory operations to classify the somatic
mutations as: early (present in all subpopulations), intermediate (shared between two subpopulations) or late (exclusive to one subpopulation) (Figure 2a-c). Strikingly, we
found that only 22.18% of the point mutations and 8.18% of
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Figure 2 Venn diagrams of shared and unique somatic mutations. Venn diagrams were constructed from different classes of somatic
mutations by comparing the three tumor subpopulations (H, AA, and AB). (a) Single nucleotide variants, (b) small insertions and deletions,
(c) structural variants, and (d) barchart of the somatic mutation percentages in each tumor subpopulation.

the indels were shared between all three tumor subpopulations. The majority of the somatic mutations were
present in two subpopulations or exclusively detected in
only one subpopulation. The AB subpopulation harbored the highest number of private point mutations
(N = 4863) and structural variants (N = 81) compared to
the other subpopulations. In contrast the AA subpopulation showed the highest number of private indels (N =
1,012). We plotted the percentage of mutation classes
by subpopulation, which clearly shows that the H subpopulation showed the fewest numbers of mutations for
all classes, suggesting that it represents one of the earliest subpopulation in the tumor (Figure 2d). We also examined the mutation spectrum of transitions and
transversions, which showed no clear differences between the subpopulations (KS test, P = 0.34). In all three
subpopulations we observed only marginal (5%) increases in C > T (G > A) transitions (Additional file 1:
Figure S4). These mutation spectrums are consistent
with recent reports from other breast cancer genome
sequencing studies [41-43].

Inferring the evolutionary lineage of the tumor
subpopulations

To gain insight into the evolutionary relationship among
tumor cell subpopulations, we constructed neighbor-joining
trees using different classes of somatic mutations (SNV,
indel, SV, and CNA). We found that all trees shared a common topology, in which the hypodiploid (H) subpopulation
was ancestral to the two sub-tetraploid AA and AB subpopulations (Figure 3a-d). A simple interpretation of this data is
a linear model of clonal evolution whereby a diploid progenitor lineage underwent catastrophic loss of whole chromosomes and chromosome arms to form an approximately
1.7 N hypodiploid cell population, followed by a single genome doubling event that gave rise to the two sub-tetraploid
subpopulations AA (3.1 N) and AB (3.3 N).
However, this naive linear model is based purely on genetic distance, and is contradicted by the large number of
somatic mutations that are shared between the AA and H
subpopulations, but absent from AB (for example, 2789
AA-H SNVs, Figure 2a). If the AA and AB subpopulations
derived from the same genome doubling event, which
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Figure 3 Genomic lineage of tumor subpopulations. (a-d) To visualize the genetic distance between tumor subpopulations, neighbor-joining
trees were constructed from distance matrices using different classes of somatic mutations. (a) Single nucleotide variant tree. (b) Indel tree. (c)
Copy number aberration tree. (d) Structural variant tree. (e) Diagram of one potential evolutionary history that can explain the patterns of variant
sharing shown in Figure 2a. Different clonal lineages inferred by Ploidy-Seq are indicated by distinct colors and roman numerals. Note that the
relative area of each clone is not representative of the actual abundance in the analyzed tumor. Key cellular ancestors are indicated by the labels
a1-a4: a1 is the last common ancestor of the genetically distinct hypodiploid clones II and III; a2 and a3 are the cells in which endoreduplication
occurred to produce clone IV and clone V, which comprise the AA population; a4 is the cell giving rise to AB (clone VI), which is the most highly
mutated subpopulation and appears to have undergone rapid clonal expansion.

necessarily must have occurred in a single cell, then due to
this single cell ‘bottleneck’ event they should both retain all
of the early somatic mutations that were shared between
that single cell and the H subpopulation as a whole, yet they
clearly do not. One possible explanation is that the 2,789
AA-H SNVs are early mutations that were lost from the AB
lineage due to late LOH events, a plausible hypothesis given
that AB has many private LOH blocks (Additional file 1:
Figure S5). To test this hypthesis, we examined overlap between SNVs and LOH events, and found that only 257 of
the 2,789 (9.2%) AA-H SNVs reside in AB-specific LOH
blocks, which is merely a 2.04-fold enrichment relative to
the number expected by chance (Additional file 1: Table S4).
Therefore, the vast majority of AA-H SNVs cannot be explained by LOH events.
This discrepancy strongly argues that multiple genome
doubling events occurred during the evolution of the
AA and AB subpopulations. One model to account for
these observations is that two endoreduplication events
occurred in genetically distinct clones of the hypodiploid
ancestral population, at approximately the same time

and physical location during tumor evolution, leading to a
sub-tetraploid AA cell population composed of two intermixed lineages (Figure 3e). The AB subpopulation then
arose from a small number of cells derived exclusively from
one of the two clones in the AA subpopulation, and subsequently underwent rapid expansion. This recent bottleneck
and clonal expansion is supported by the high allele frequency of SNPs contained within LOH events in the AB
relative to the AA and H subpopulation (Additional file 1:
Figure S5 and Figure S6a), as well as the relatively high frequency of AB-specific SNVs (Additional file 1: Figure S6f).
An alternative model invokes cell fusion (Additional file 1:
Figure S7b). Here, a hypodiploid ancestor of AA and AB diverged from the H subpopulation for a long period of time,
acquiring numerous mutations that are not present in H
(AA-AB markers). This ancestral lineage gave rise to the AA
sub-tetraploid clone through a cell fusion event with a cell
closely related to the H subpopulation, and gave rise to the
AB sub-tetraploid clone through an endoreduplication
event. Although cell fusion has been studied extensively in
cell culture and has been proposed as a mechanism of
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tumor evolution [44], it has to our knowledge not been definitively shown to occur in endogenous human tumors (although some anecdotal evidence has been reported [45]).
Thus, we conclude that the first model is more likely, since
it involves two independent occurrences of endoreduplication, which is well established mechanism for tetraploidization [46]. Moreover, although most of the observed SNV
allele frequency distributions (Additional file 1: Figure S6)
are consistent with either model, the cell fusion model
strongly predicts that AA-AB SNVs should be fixed within
both the AA and AB lineages due to their respective single
cell bottleneck events, and therefore be present at an allele
frequency of precisely 25% in the AA subpopulation (one of
four chromosomes due to cell fusion) and 50% in AB (two
of four chromosomes due to endoreduplication). In contrast,
the observed mean allele frequencies of AA-AB SNVs in
AA and AB subpopulations are substantially lower (13% and
32%, respectively), which is more consistent with the dual
endoreduplication model.
Thus, our data strongly suggest that the AA subpopulation is composed of two major clones, each derived
from an independent endoreduplication event in genetically distinct cells of the ancestral H subpopulation.
This is to our knowledge the first evidence that multiple
genome doubling events may occur within a single
tumor, and suggests that such events may be surprisingly
common. A caveat is that these data also show an inherent limitation of Ploidy-Seq: it is not possible by flow
sorting to distinguish between cells that have distinct
evolutionary histories yet similar ploidy, and thus it is
important to recognize that genetically distinct clones
may exist within flow-sorted cell populations. Nonetheless, by greatly simplifying the problem of reconstructing
tumor evolution, Ploidy-Seq allows novel insights that
would be missed by bulk sequencing.
Inferring the ancestral tumor genome

We used the mutational data from the three tumor subpopulations to infer the ancestral genome (n1) from which
all subpopulations emerged (Figure 4). This ancestral genome showed a reduced number of somatic mutations
(SNVs, indels, LOH, SVs, and CNAs) compared to the advanced subpopulations, allowing us to identify mutations
that played an important role in the early stages of tumor
progression. Among the 83 non-synonymous mutations
that occurred throughout tumor evolution, we identified
nine early non-synonymous point mutations that occurred
in cancer genes (Additional file 2: Table S1). Only five of
these mutations (TP53, PPP2R5B, FBXO11, PORCN, and
NOX4) were predicted to have damaging effects on protein
function as predicted by SIFT (<0.1) and POLYPHEN
(>0.5) scores [47,48]. Among these, we found a salient mutation in exon 7 in the DNA binding domain of TP53. This
mutation (Y234C) was previously reported 82 times in the
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COSMIC database [31] at the same nucleotide position,
suggesting that it is a strong driver mutation. However, the
TP53 mutation was unlikely to be acting alone: two other
early mutations (PPP2R5B and FBX011) were detected, and
have previously been reported to interact with TP53 to promote tumor growth. PPP2R5B was reported to have a
tumor suppressor activity by interacting with PP2A to mediate dephosphorylation of TP53 in response to DNA damage [49]. FBX011 is an adapter protein that has been shown
to promote neddylation of p53 and inhibit its transcriptional activity [50]. We also detected an early mutation in
PORCN, which is an upstream regulator of the WNT signaling pathway and in NOX4, which is an NADPH oxidase
involved in the generation of hydrogen peroxide and superoxide [51]. We speculate that the NOX4 mutation may have
increased the reactive oxygen species and mutation rate in
the tumor microenvironment. We also detected an early
structural rearrangement, a 1,058 bp deletion in exon5 of
MLLT3, a gene that is often translocated in leukemias
(Additional file 2: Table S3), and early copy number
changes, including a gain of chromosome 1q and loss of 1p,
amplification of chromosome 8q (MYC) and loss of 17p.
These mutations may have acted together to drive the early
stages of tumor progression in this patient.
Inferring the chronology of somatic mutations

We also identified a number of mutations that occurred
during the intermediate and late stages of tumor progression
(Figure 5) (Additional file 2: Table S1). Overall, we observed
that early mutations showed higher allele frequencies when
compared to the intermediate (P = 0.026, t-test) and late
(P = 0.0015, t-test) mutations (Figure 5a). As expected from
the phylogenetic analysis, many of the intermediate nonsynonymous mutations were shared between the H and AA
subpopulations, and the AA and AB subpopulations, but
not shared between H and AB. Two intermediate mutations
in the H and AA subpopulations (CDK8 and RAB3A) were
predicted to have damaging effects on protein function by
SIFT and POLYPHEN scores (Additional file 2: Table S1).
These mutations were not detected in the AB subpopulation, suggesting that they are not likely to be important in
the late stages of tumor progression. After the divergence of
the second common ancestor (n2) we detected mutations in
NOTCH1, BCOR, and CCND3, which all showed significant
POLYPHEN and SIFT scores (Additional file 2: Table S1).
The NOTCH1 mutation (M1615I) occurred in the NOD domain and is likely to be a driver mutation, since it was previously reported at the same nucleotide position in the
COSMIC database. NOTCH1 is involved in many cellular
signaling processes associated with development and cell
fate and has recently been suggested to be a novel oncogene
in breast cancer [52].
Interestingly, many of the late mutations occurred exclusively in the minor AB subpopulation. We detected
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Figure 4 Inferred ancestral tumor genome. Circos plot of the n1 ancestral tumor genome that was inferred by identifying the common set of
somatic mutations in the H, AA, and AB tumor subpopulations. Somatic mutations in cancer genes are displayed on the outer ring, while
different classes of somatic mutations are displayed in the inner rings.

three non-synonymous mutations in cancer genes, including a nonsense mutation in RPTOR and point mutations in PIK3C2B and SMARCA4. RPTOR is a gene that
interacts with mTOR to regulate the signaling of cellular
proliferation and survival [53]. PIK3C2B is a member of
the PI3 Kinase family pathway involved in regulating cell
proliferation, survival, and migration [54]. The AB subpopulation also showed a 50-fold copy number amplification of the KRAS locus on chromosome 12p12.1 and

two homozygous deletions of the EFNA5 and COL5A4
tumor suppressors. Thus, while AB was the rarest subpopulation in the tumor (about 8% of the tumor mass) it also
harbored the largest number of cancer gene mutations.
Interestingly, the AB allele frequencies suggest that AB
underwent a recent population bottleneck (Additional file 1:
Figure S5f), and thus we infer that these mutations provided
a strong selective advantage, allowing the subpopulation to
expand rapidly.
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Figure 5 Chronology of somatic mutations and interaction networks. (a-c) Non-synonymous point mutations detected in the breast tumor
subpopulations (a) Distribution of allele frequencies of the non-synonymous mutations. (b) Heatmap of the non-synonymous mutations ordered by relative
chronology. Point mutations in cancer genes are highlighted in red. (c) Percentage of somatic mutations detected in the TCGA breast tumor patient cohort.
(d) Network analysis of the point mutations that were temporally deregulated during tumor evolution. (e) Detection efficiency of simulated bulk data at
different coverage depths.
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We compared all of the significant somatic mutations detected in this study to the breast cancer mutations reported
in the Cancer Genome Atlas (TCGA) (Figure 5c). We
found that the majority (74%) of the point mutations were
previously reported in TCGA, but often occurred at low
frequencies in the patient cohort (<3%). The exception was
TP53, which was reported to occur in 37% of the TCGA
breast cancer patients.
Pathway and network analysis

To determine if any signaling pathways were deregulated
by acquiring multiple somatic mutations during tumor evolution, we used the non-synonymous point mutations to
perform pathway analysis (methods). Our data suggest that
the Wnt Signaling pathway was the only pathway to show a
statistically significant enrichment (P = 0.083) of mutations.
Interestingly, mutations in this pathway accumulated progressively as the tumor evolved. The earliest mutations occurred in PORCN, CDH26, PPP2R5B, and TP53 and were
present in all three subpopulations (H, AA, AB). This was
followed by an intermediate mutation in CCND3 that occurred in the n2 ancestor and was present in both AA and
AB. Finally late mutations occurred in CTBP2 and
SMARCA4 in the AB subpopulation. Wnt signaling is involved in regulating cell-to-cell interactions during embryogenesis, and many mutations in this pathway have been
associated with cancer progression [55,56].
We also performed network analysis to identify larger networks beyond individual pathways that were disrupted during tumor evolution (methods). These networks are based
on direct protein interaction data or protein modifications
(Figure 5d). Consistent with our previous results, the network analysis revealed multiple mutations involved in regulating genome instability in the TP53 network, including
TP53, FBXO11, PPP2R5B, RBL2, and SMC3 (P = 0.009,
Fisher’s exact test). The extended network also included
early mutations involved in regulating nuclear transcription
(NCOA3) and cell cycle (RBL2). We also found an intermediate mutation in cyclin D3 (CCND3), which interacts
with RBL2, and a mutation in NOTCH1 involved in regulating differentiation. The late mutations in this network were
found to be involved in regulating cell proliferation. A late
mutation was found in PIK3C2B which interacts with
PIK3CA, one of the most frequent mutations that has been
reported in breast cancer [43,57]. The other late mutation in
this network occurred in RPTOR, a gene that regulates cell
proliferation and apoptosis. All of the late mutations that
deregulated the TP53 network (Figure 5d) occurred exclusively in the AB subpopulation, which comprised the minority of the tumor mass. The early mutations occurred in all
three subpopulations, while the intermediate mutations
were found in both the AA and AB subpopulations. In summary, these data shows a complex interplay of different cellular processes (genome instability, cell cycle, proliferation,
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survival, apoptosis, and differentiation) that were deregulated at progressive stages of tumor growth.
Simulating data from bulk tumor tissues

In order to estimate the number of mutations that would
have been detected by sequencing the bulk tumor en
masse, we performed in silico mixing experiments. We
combined raw sequence data from the three tumor subpopulations in proportion to the numbers of cells detected
in the cytometric data to obtain mixtures of reads corresponding to 30X, 50X, and 100X mean sequence coverage
(see Methods). From these data we detected genome-wide
somatic SNVs using the same processing pipeline that was
used to detect mutations in the tumor subpopulations
(methods). We then compared the total number of point
mutations detected from deep-sequencing the three tumor
subpopulations separately to the combined simulation
data at different sequencing depths. We found that only
30% of the mutations were detected at 30X coverage,
while 38% were detected at 50X and 43% were detected at
100X (Figure 5e). Thus, our data suggest that the majority
of mutations would have been missed entirely by sequencing the bulk tumor en masse at standard sequencing
depths.
Computational estimations from bulk sequencing data

Several recent computational methods have been developed to estimate clonal subpopulations from bulk NGS
data by clustering mutation frequencies [37,58-60]. We
applied two computational methods (SciClone and PurBayes) that cluster mutation frequencies and use Bayesian mixture models to identify the correct number of
clusters that correspond to clonal subpopulations. In
these methods, it is assumed that the mutation clusters
correspond directly to the individual subpopulations in
the tumor [30,31]. To perform these analyses we used
the in silico mixed datasets to represent bulk sequencing
at different coverage depths (30X, 50X, and 100X). Both
methods used the copy number profiles of the mixed
data to identify copy-neutral mutations, which were used
filter regions of the genome that contain CNAs that
might skew the mutation frequencies. SciClone analysis
[37] predicted only a single cluster that corresponded to
one subpopulation of tumor cells, even at the highest
(100X) coverage depth (Additional file 1: Figure S8).
Similarly, PurBayes [38] identified only a single cluster
that corresponded to one clonal subpopulations at 30X
or 50X coverage depth (Additional file 1: Figure S9a, b).
However, PurBayes did stratify the 100X mixed SNV
dataset into two separate clusters that may potentially
correspond to clonal subpopulations. However, when we
compared the mutations from these two clusters to the
H, AA, and AB subpopulations detected by Ploidy-Seq,
we found no clear correlation: the mutations in each
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cluster were found in all three subpopulations. Next, we
sought to determine if the computational methods could
reveal further substructure in the flow-sorted subpopulation datasets (H, AA, and AB). We applied SciClone to the
data generated by Ploidy-Seq and found that no further
clusters or subpopulations could be detected in the H, AA
or AB datasets (Additional file 1: Figure S8b-d). Therefore,
we conclude that bulk tumor sequencing and computational inference methods could not resolve the same population substructure that was resolved by Ploidy-Seq analysis
in this tumor.

Discussion
In this study we present a novel approach for reconstructing genome evolution from polyploidy tumors. Our method
involves isolating and comparing somatic mutations in different subpopulations to trace lineage and infer mutational
chronology. We applied this method to study genome evolution in a triple-negative breast tumor, by sequencing three
tumor subpopulations and a population of diploid cells.
Our data revealed a highly complex tumor, harboring thousands of somatic mutations, including point mutations,
indels, structural variants, and copy number aberrations.
Strikingly, we found that only 22.18% of the point mutations and 8.18% the indels were shared between all three
subpopulations. These results are consistent with a recent
report in which tumor cells were spatially sampled from
kidney tumors [61] and found to share only 63% to 69% of
SNVs among all sampled regions. The shared mutations we
identified were present in all of the tumor subpopulations
and thus represent the earliest mutations that occurred
during tumor progression. Among them we identified an
early driver mutation in exon 7 of TP53. There is much debate in the field as to whether TP53 plays an important role
in the early stages of tumor progression [62]. Our data
strongly suggest that the TP53 mutation was an early
founder mutation that was inherited by all subsequent subpopulations. However, the TP53 mutation was unlikely to
be operating alone, since we also detected mutations in
FBXO11 and PPP2R5B, which have been shown to interact
with TP53 to drive tumor growth [49,50]. These early mutations were present in all of the tumor cells, suggesting origin from a common ancestor that evolved from a single cell
in the normal breast tissue of this patient.
Using genetic mutations as stable markers of evolution,
we reconstructed the phylogenetic lineage of the tumor. A
simple interpretation of the data was a linear pathway
in which a single normal cell underwent genome-wide
chromosome losses to form the H subpopulation (1.7 N)
followed by a genome duplication to generate the AA
(3.1 N) and AB (3.3 N) subpopulations. This model is supported by neighbor joining trees constructed from multiple mutation datasets (SNVs, indels, CNAS, and SVs).
However, this model is contradicted by a large number of
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somatic mutations that are shared between the H and AA
subpopulations, but absent from AB, which cannot be explained by trivial reasons such as LOH. Instead, these mutations imply a more complex model of evolution in
which two independent genome duplication events occurred in the lineage giving rise to the AA and AB subpopulations. The mechanism underlying these genome
duplication events are unknown, but may have been due
to either cell fusion or endoreduplication. Our current
data are not sufficient to definitively distinguish between
these mechanisms, but the observed SNV allele frequencies (Additional file 1: Figure S6) are more consistent with
endoreduplication. Endoreduplication is a well established
mechanism for genome duplication in human cancers,
while evidence for cell fusion has been limited to cell culture experiments [44] and a single tumor from a bone
marrow transplant patient [45].
The genome doubling events subsequently led to the formation of two minor subpopulations (AA and AB) in the
tumor that comprised approximately 8% and 10% of the
total tumor mass. While minor, these subpopulations contained many additional somatic mutations, including shared
mutations in cancer genes including NOTCH1, CCND3,
and BCOR. The AB subpopulation showed the highest
number of somatic mutations, including point mutations in
RPTOR and PIK3C2B and a massive 50-fold amplification
in the KRAS oncogene as well as focal homozygous deletions of the EFNA5 and COL4A5 tumor suppressors. These
mutations may have led to an increase in cell proliferation
and migration, and an inhibition of apoptosis. Our data suggest that the minor subpopulations were the most malignant
cells in the tumor. Importantly, this was a treatment-naïve
tumor sample, and thus the evolutionary lineages occurred
through natural selective pressures in the tumor microenvironment, rather than selective agents.
Recent reports from large-scale sequencing projects
have identified thousands of nonsynonymous mutations
in breast cancer genomes [7,15,43,57], but surprisingly
few mutations that are shared between individual patients.
In triple-negative breast cancer TP53 is the only mutations that occurs at a high percent of patients (80%), while
the vast majority of mutations (including PIK3CA, RB1,
PTEN, MYO3A, and GH1) occur at low percentages
(<10%) in the patient cohorts [7]. On average, these studies identified only a few (one to five) driver mutations in
cancer genes in each patient’s tumor. In contrast, we identified 20 non-synonymous driver mutations in cancer
genes in this TNBC patient, many of which occurred in
the minor subpopulations. When we compared these mutations to the TCGA data, we found that most of the
mutations (74%) were previously detected in other breast
cancer patient genomes. Thus, our data may indicate that
many additional somatic mutations may be shared
between different patients, but reside in minor tumor
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subpopulations and thus go undetected at standard sequencing depths. We simulated reads at different sequence
depths for variant detection and found that most of the late
and intermediate mutations would have been missed entirely by bulk sequencing at standard coverage depth. These
data show the importance of using methods such as PloidySeq or ultra-deep sequencing in order to identify mutations
in minor subpopulations that may play an important role in
tumor progression, invasion, and metastasis.
We previously analyzed copy number evolution in this
tumor using single-cell sequencing [11] and spatial sampling by microarray CGH [4]. The copy number profiles
from these studies are consistent with our current analysis,
by showing that the tumor cells were organized into three
major clonal subpopulations (H, AA, and AB), each sharing
the majority of amplification and deletions. These data also
showed a common genetic lineage, suggesting an origin
from a single somatic cell in the breast. However, the
current studies provide further insight into the clonal substructure and evolution of point mutations, indels, and
structural variants in addition to CNAs that occurred during tumor evolution.
Our data have important implications for the clinical
diagnosis and treatment of TNBC patients. First, we show
that tumor subpopulations can be spatially segregated in
the tumor and carry distinct sets of somatic mutations
that reside in different geographical regions. This has important implications for diagnostic testing, because we
would not have detected mutations in KRAS or RPTOR in
the upper regions of the tumor mass. This ‘spatial heterogeneity’ in tumors is becoming more widely recognized in
solid tumors [4,61,63] as research studies begin to sample
multiple regions within solid tumors for genomic studies.
Our data also have important implications for targeted
therapy, by showing that early mutations are likely to be
ideal targets for therapy, since they are molecular targets
that are present in the majority of the tumor cells. In theory, we should be able to eradicate the entire tumor mass
by targeting these mutations, since they are present in
most of the tumor cells. Alternatively, we can design different therapeutic strategies to target each of the tumor
subpopulations independently using the intermediate and
late mutations.
To identify potential drug targets in this TNBC patient we
annotated all cancer gene mutations using the Drug-Gene
Interaction Database (Additional file 2: Table S1). We did
not identify any early mutations that could serve as direct
targets for therapy, since TP53 is notoriously difficult to target in cancer cells without disrupting its function in normal
cells. However, we did identify an intermediate mutation in
CDK8 that is present in the H and AA subpopulations that
may be targeted with Flavopiridol, a cyclin-dependant kinase
inhibitor. We also identified an intermediate mutation in
Cyclin D (CCND3) that could be targeted with several drugs
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that are currently in clinical trials (LY2835219, LEE011,
BAY1000394), or Palbociclib. In the late AB subpopulation
we also identified mutations in PIK3C2B and RPTOR, which
may sensitize the tumor to a number of drugs that target
the PI3K/Akt/mTOR signaling pathways. Targeting the AB
subpopulation specifically might have been very beneficial to
the patient, since we suspect that the AB subpopulation was
the most malignant in the tumor.
While Ploidy-Seq can provide a powerful approach for
study genome evolution and clonal diversity in human tumors, there are also several notable limitations. Foremost,
the method requires tumors that are polyploidy and have
aneuploid peaks that do not overlap in ploidy with the
diploid peaks, or with each other. We estimate that about
half of all breast tumors contain such ploidy distributions
based on our cytometric analysis (Additional file 2: Table
S1). Another possible limitation (and all sequencing studies) is the sensitivity with which the mutations were detected in each of the tumor subpopulations. At a mean
depth of 53.75X it is possible that some mutations, which
we classified as ‘private’, do in fact exist in other tumor
subpopulations, but at frequencies below our detection
limits. These mutations may be detected at higher sequence read depths, but then become difficult to distinguish from sequencing errors without methods such as
duplex sequencing [64]. In summary, the genomic diversity reported in this study is likely to be an underestimate
of the clonal diversity in the tumor.
Finally, we note that the data presented here were derived
from a single cancer patient, and thus our findings may not
be generalizable to all TNBC patients. Future work will be
needed, in a larger set of TNBC patients, to determine if:
(1) tetraploidy through chromosome loss is a common
mechanism of genome evolution; (2) large numbers of private mutations are common in tumor subpopulations; (3)
tumor subpopulations are often geographically segregated
with the tumor mass; and (4) early mutations in TP53 drive
tumor growth in breast cancer. Furthermore, it will be of
great interest to identify the selective pressures in the
tumor microenvironment (immune system, hypoxia, geographic isolation, nutrient deprivation) that cause lineages
to diverge, resulting in the intratumor heterogeneity. We
fully expect that these findings and novel methods for resolving intratumor heterogeneity will lead to improvements
in the clinical diagnosis and therapeutic targeting of breast
cancer patients.

Conclusions
Ploidy-Seq provides a powerful new approach to isolate
and study subpopulations within solid tumors. Using this
tool, we studied genomic diversity and evolution in a
triple-negative breast cancer patient, which revealed several important biological findings regarding genome evolution. Our data show that breast tumors can evolve by
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chromosome loss, followed by genome duplication to
generate tetraploidy. We also identified a large number
of private mutations that resided in minor tumor subpopulations and were not shared by the neighboring
tumor cells. By inferring the ancestral tumor genome,
we identified a subset of somatic mutations that play an
important role in the early stages of tumor progression,
including an early driver mutation in TP53. These data
provide new insight into genome evolution in breast
cancer and would not have been revealed by sequencing
the bulk tumor en masse.
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